Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292809 · ClinicalTrials.gov registry record · Phase 2
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 2 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT03292809 is a Phase 2 study that has completed, run by Novaliq. The registered enrollment target is 328 participants.
The verdict
NCT03292809, a Phase 2 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
Interventions
- DRUG CyclASol topical ocular, eye drops
- DRUG Vehicle topical ocular, eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2018-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03292809
The ClinicalTrials.gov registry entry for NCT03292809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novaliq, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CyclASol topical ocular, eye drops is the first listed.
NCT03292809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03292809 about?
NCT03292809 is a clinical study titled "CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)". The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
What is the current status of trial NCT03292809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2017-10-19. Estimated completion is 2018-06-20.
What interventions are being tested in trial NCT03292809?
The interventions under investigation include: CyclASol topical ocular, eye drops (DRUG), Vehicle topical ocular, eye drops (DRUG).
Who is sponsoring clinical trial NCT03292809?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.